MAP3K8 Polyclonal Antibody, HRP Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-3591R-HRP |
| Product Name | MAP3K8 Polyclonal Antibody, HRP Conjugated |
| Applications |
WB
ELISA
IHC-P
|
| Reactivity | Mouse |
| Predicted Reactivity | Human, Rat, Dog, Cow, Horse, Chicken, Rabbit |
| Specifications | |
| Conjugation | HRP |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human MAP3K8 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 1326 |
| Swiss Prot | P41279 |
| Subcellular location | Cytoplasm |
| Synonyms | COT; EST; ESTF; TPL2; MEKK8; Tpl-2; c-COT; Mitogen-activated protein kinase kinase kinase 8; Cancer Osaka thyroid oncogene; Proto-oncogene c-Cot; Serine/threonine-protein kinase cot; Tumor progression locus 2; MAP3K8 |
| Background | Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant. |
| Application Dilution | |
| WB | 1:300-5000 |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
Frequently asked questions
Which applications is MAP3K8 Polyclonal Antibody, HRP Conjugated (bs-3591R-HRP) validated for, and at what dilution?
bs-3591R-HRP is validated for WB (1:300-5000); ELISA (1:500-1000); IHC-P (1:200-400). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does MAP3K8 Polyclonal Antibody, HRP Conjugated (bs-3591R-HRP) react with?
Tested reactivity: Mouse. Predicted reactivity (expected from sequence homology but not yet tested): Human, Rat, Dog, Cow, Horse, Chicken, Rabbit.
How should bs-3591R-HRP be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise MAP3K8 Polyclonal Antibody, HRP Conjugated (bs-3591R-HRP)?
KLH conjugated synthetic peptide derived from human MAP3K8